Parameter
| Biomarker | MGMT Promoter Meth | Full name | O6-Methylguanine-DNA Methyltransferase Promoter Methylation | Molecular Type | DNA Methylation |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Prediction, Pharmacodynamics/Response |
| Disease | Epilepsy | Disease Subtypes | / | ||
| Organ | Brain | Test Sample / Technology Platform | Tumor Tissue (MSP, Pyrosequencing) | ||
| Pathobiological Mechanisms | Methylation silences the MGMT gene, reduces DNA repair, and enhances the efficacy of temozolomide on epilepsy-related brain tumors. | ||||
| Clinical Availability Status | Research validation stage | ||||
| Notes and Dynamics | The epilepsy control rate of chemotherapy combined with ASM treatment is increased by 40% in methylation-positive patients. | ||||